HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.

Abstract
Intravesical instillations of BCG are effective in preventing tumor recurrence, eliminating existing tumor and treating CIS in a substantial number of patients. As with any type of therapy, side effects can occur. Because a live organism is being used, care must be taken in the handling and administration of the product. Patients should be informed about the common types of reactions so that these may be reported to the urologist. In turn, the urologist must decide if the treatment plan needs to be modified or the patient started on medications which can prevent or reduce the severity of the side effects. At times a decision must be made regarding withholding or delaying treatment and there are situations when BCG should be stopped.
AuthorsS A Brosman, D L Lamm, A P van der Meijden, F M Debruyne
JournalProgress in clinical and biological research (Prog Clin Biol Res) Vol. 310 Pg. 311-23 ( 1989) ISSN: 0361-7742 [Print] United States
PMID2672019 (Publication Type: Journal Article, Review)
Chemical References
  • BCG Vaccine
Topics
  • Administration, Intravesical
  • BCG Vaccine (administration & dosage, adverse effects, therapeutic use)
  • Carcinoma in Situ (therapy)
  • Carcinoma, Transitional Cell (therapy)
  • Clinical Protocols
  • Humans
  • Neoplasm Recurrence, Local
  • Urinary Bladder Neoplasms (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: